Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.…
Xenetic Biosciences Reports Third Quarter 2026 Financial Results and Highlights Strategic Business Updates
Xenetic Biosciences (NASDAQ: XBIO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 2 employees.
The shares were at 1.400 USD on 20 November 2026, down 48.5% over 52 weeks. Its 52-week range is 1.250 USD to 4.939 USD: the price is 71.7% below the high and 12.0% above the low.
Its market capitalisation is 3.28M USD.
Xenetic Biosciences reports return on equity of -36.2%, an operating margin of -81.0% and revenue up 12.0% year over year.
It holds more cash than debt, a net cash position of 6.47M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.